- Home
- BCV vs KRRO Comparison
BCV vs KRRO Comparison
Compare BCV & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- KRRO
- Stock Information
- Founded
- BCV 1971
- KRRO 2014
- Country
- BCV United States
- KRRO United States
- Employees
- BCV N/A
- KRRO N/A
- Industry
- BCV Finance/Investors Services
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- BCV Finance
- KRRO Health Care
- Exchange
- BCV Nasdaq
- KRRO Nasdaq
- Market Cap
- BCV 104.8M
- KRRO 101.4M
- IPO Year
- BCV N/A
- KRRO 2019
- Fundamental
- Price
- BCV $18.26
- KRRO $12.35
- Analyst Decision
- BCV
- KRRO Strong Buy
- Analyst Count
- BCV 0
- KRRO 7
- Target Price
- BCV N/A
- KRRO $85.67
- AVG Volume (30 Days)
- BCV 26.3K
- KRRO 203.4K
- Earning Date
- BCV 01-01-0001
- KRRO 08-12-2025
- Dividend Yield
- BCV 8.13%
- KRRO N/A
- EPS Growth
- BCV N/A
- KRRO N/A
- EPS
- BCV N/A
- KRRO N/A
- Revenue
- BCV N/A
- KRRO $4,821,000.00
- Revenue This Year
- BCV N/A
- KRRO $65.08
- Revenue Next Year
- BCV N/A
- KRRO N/A
- P/E Ratio
- BCV N/A
- KRRO N/A
- Revenue Growth
- BCV N/A
- KRRO N/A
- 52 Week Low
- BCV $14.09
- KRRO $10.29
- 52 Week High
- BCV $18.11
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- BCV 50.83
- KRRO 41.55
- Support Level
- BCV $18.17
- KRRO $11.50
- Resistance Level
- BCV $18.49
- KRRO $16.86
- Average True Range (ATR)
- BCV 0.17
- KRRO 1.50
- MACD
- BCV -0.06
- KRRO 0.01
- Stochastic Oscillator
- BCV 32.67
- KRRO 31.35
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.